中等度から重度のクローン病（CD）の小児および10代の若者を対象としたベドリズマブの研究

基本情報

NCT ID

NCT04779320

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

120

治験依頼者名

Takeda

概要

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive either a high dose or low dose of vedolizumab once every 8 weeks. They will receive the same dose every time.

対象疾患

介入

依頼者（Sponsor）

実施施設 (4)